It is hard to see a combination of the two businesses as much beyond a defensive move in troubled times.
The novel schizophrenia candidate KarXT will head to regulators after a win in Emergent-2.
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
Pivotal data will show whether KarXT can walk the risk-benefit tightrope.
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
The group’s deal with Sosei will see it compete with Karuna and Cerevel.
Early stage schizophrenia data have seen the group double in value, but there are a couple of sticking points.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.